1. Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia. Drug Delivery, 2017, 24: 882–890. 2. A novel immunoliposome mediated by CD123 antibody targeting to acute myeloid leukemia cells. International Journal of Pharmaceutics. 2017, 529: 531–542. 3. Development of Synthetic Peptide-Modified Liposomes with LDL Receptor Targeting Capacity and Improved Anticancer Activity. Molecular Pharmaceutics. 2014,11:2305-2312.(通讯作者) 4. Development of Intravenous Lipid Emulsion of α-asarone with Significantly Improved Safety and Enhanced Efficacy. International Journal of Pharmaceutics.2013,450:21-30.(通讯作者) 5. Development of intravenous lipid emulsion of tanshinoneⅡA and evaluation ofits anti-hepatomaactivity in vitro. International Journal of Pharaceutics.2012,424:76-88.(通讯作者) 6. Development of 2-hydroxymethyl-3,5,6-trimethylpyrazine palmitate-loaded lipid emulsion: formulation,optimization, characterization, pharmacokinetics,biodistribution and pharmacodynamics. Journal of Drug Targeting.2013,21:341-353.(通讯作者) 7. Formulation optimization of prostaglandin E1-loaded lipid emulsion: Enhanced stability and reduced biodegradation. Pharmaceutical Development and Technology.2013,18:804-812.(通讯作者) 8. Growth Inhibitory and Apoptosis Inducing Effects of Tanshinones on Hematological Malignancy Cells and their Structure-Activity Relationship. Anti-Cancer Drugs.2012,23:846-855.(通讯作者) 9. Preparation, characterization and uptake by primary cultured rat hepatocytes of liposomes surface-modified with glycyrrhetinic acid.Die Pharmazie.2007,62:614-619.（第1作者） 10. Ion-pair reversed-phase HPLC method for determination of sodium tanshinoneⅡA sulfonate in biological samples and its pharmacokinetics and biodistribution in mice. Chemical & Pharmaceutical Bulletin.2007,55:753-757.（第1作者） 11. Ion-pair reversed-phase HPLC: Assay validation of sodium tanshinone IIA sulfonate in mouse plasma.Journal of Chromatography B. 2006,831:163-168.（第1作者）
